




Supplementary Fig. 1




Penicillin G MIC distribution



Ampicillin MIC distribution




Minocycline MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Erythromycin MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)


Chloramphenicol MIC distribution




Cefotaxime MIC distribution




Cefozopran MIC distribution



Cefepime MIC distribution




Clindamycin MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Levofloxacin MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Meropenem MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Vancomycin MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Ceftriaxone MIC distribution




MIC, minimum inhibitory concentration MIC (µg/mL)

Azithromycin MIC distribution



MIC, minimum inhibitory concentration MIC (µg/mL)

Supplementary Fig. 3



Legend

The goeBURST diagram of antimicrobial susceptibility patterns by *Streptococcus uberis* strains. The numbers in the circles show sequence types (STs), and the numbers near the lines indicate the numbers of differing alleles between two connected STs. Putative clonal complexes (CCs) are identified by an outer dotted frame and correspond to STs with the highest numbers containing single-locus/double-locus/triple-locus variants. Light violet and light blue in the circles represent multidrug resistant strains (n = 24) and susceptible strains (n = 7), respectively. GCCs, global clonal complexes.

Supplementary Table 1. Fourteen antimicrobial minimum inhibitory concentrations (µg/mL) against each isolate with susceptibility results and antimicrobial resistance (AMR) genotype of each isolate																											
Isolate (prefecture)	Collection date (year/month)	Penicillin G	Ampicillin	Minocycline	Erythromycin	Chloramphenicol	Cefotaxime	Cefazopran	Cefepime	Clindamycin	Levofloxacin	Meropenem	Vanco mycin	Ceftriaxone	Azithro mycin	<i>blaZ</i>	<i>erm</i> (A)	<i>erm</i> (B)	<i>mef</i> (A)	<i>linB</i>	<i>lnuD</i>	<i>tet</i> (M)	<i>tet</i> (O)	<i>tet</i> (K)	<i>tet</i> (L)	<i>tet</i> (S)	
UB1 (Chiba)	2022/Mar	0.12	0.25	>4	>2	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB2 (Chiba)	2022/Mar	0.12	0.12	>4	>2	≤0.12	0.5	0.25	<0.5	>1	1	0.25	0.5	0.25	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB3 (Chiba)	2022/Mar	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	≤0.12	0.5	0.25	≤0.25												
UB4 (Chiba)	2022/Mar	0.12	0.12	>4	≤0.12	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.25	≤0.25						<i>lnuD</i>					<i>tet</i> (S)	
UB5 (Chiba)	2022/Apr	0.12	0.12	≤0.5	≤0.12	≤0.12	1	0.5	<0.5	>1	≤0.25	0.5	0.5	0.5	≤0.25					<i>linB</i>							
UB6 (Chiba)	2022/Apr	0.12	0.12	≤0.5	≤0.12	≤0.12	1	0.5	<0.5	>1	0.5	≤0.12	0.5	1	≤0.25					<i>linB</i>							
UB7 (Chiba)	2022/Apr	0.12	0.12	>4	>2	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.25	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB8 (Chiba)	2022/Apr	0.06	0.12	>4	≤0.12	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.25	≤0.25					<i>linB</i>	<i>lnuD</i>					<i>tet</i> (S)	
UB9 (Chiba)	2022/May	0.06	≤0.06	≤0.5	≤0.12	≤0.12	0.25	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	0.25	≤0.25												
UB10 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	≤0.12	≤0.25	≤0.12	0.5	0.5	≤0.25												
UB11 (Chiba)	2022/May	0.06	0.12	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	≤0.12	0.5	≤0.12	0.5	0.5	≤0.25												
UB12 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25												
UB13 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25						<i>lnuD</i>						
UB14 (Chiba)	2022/May	0.12	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	1	≤0.12	0.5	≤0.12	≤0.25												
UB15 (Chiba)	2022/May	0.12	0.12	>4	>2	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB16 (Chiba)	2022/May	0.12	0.25	>4	≤0.12	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25					<i>linB</i>	<i>lnuD</i>					<i>tet</i> (S)	
UB17 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	≤0.12	0.5	0.5	≤0.25												
UB18 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.25	0.25	<0.5	>1	0.5	0.5	0.5	0.5	≤0.25						<i>lnuD</i>						
UB19 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	≤0.12	0.5	0.5	≤0.25												
UB20 (Chiba)	2022/May	0.12	0.12	≤0.5	≤0.12	≤0.12	0.25	0.25	<0.5	>1	0.5	≤0.12	0.5	0.25	≤0.25					<i>linB</i>	<i>lnuD</i>						
UB21 (Chiba)	2022/May	0.06	0.12	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	≤0.12	0.5	0.25	≤0.25						<i>lnuD</i>						
UB22 (Chiba)	2022/May	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25												
UB23 (Chiba)	2022/May	≤0.03	≤0.06	>4	>2	≤0.12	≤0.12	≤0.12	<0.5	>1	0.5	≤0.12	0.5	≤0.12	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB24 (Chiba)	2022/May	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25												
UB25 (Chiba)	2022/Jun	0.12	0.12	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB26 (Chiba)	2022/Jun	0.12	0.25	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25						<i>lnuD</i>						
UB28 (Chiba)	2022/Jun	0.25	0.25	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4	<i>blaZ</i>		<i>erm</i> (B)					<i>tet</i> (O)				
UB29 (Chiba)	2022/Jun	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25												
UB30 (Chiba)	2022/Jun	0.12	0.12	≤0.5	≤0.12	≤0.12	1	0.5	<0.5	≤0.12	0.5	≤0.12	1	0.5	≤0.25												
UB31 (Chiba)	2022/Jun	0.12	0.25	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25												
UB32 (Chiba)	2022/Jun	0.12	0.25	>4	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25						<i>lnuD</i>					<i>tet</i> (S)	
UB33 (Chiba)	2022/Jun	0.12	0.25	>4	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25						<i>lnuD</i>					<i>tet</i> (S)	
UB34 (Chiba)	2022/Jun	0.12	0.25	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25												
UB35 (Chiba)	2022/Jun	0.12	0.12	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	≤0.12	0.5	≤0.12	0.5	0.5	≤0.25												
UB36 (Chiba)	2022/Jun	0.12	0.25	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB37 (Chiba)	2022/Jun	0.25	0.25	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB38 (Chiba)	2022/Jun	0.12	0.25	>4	>2	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB40 (Chiba)	2022/Jun	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25									<i>tet</i> (O)			
UB41 (Chiba)	2022/Jun	0.12	0.25	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB42 (Chiba)	2022/Jul	0.12	0.12	>4	≤0.12	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25					<i>linB</i>	<i>lnuD</i>					<i>tet</i> (S)	
UB44 (Chiba)	2022/Jul	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	≤0.12	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25												
UB45 (Chiba)	2022/Jul	≤0.03	≤0.06	≤0.5	≤0.12	≤0.12	0.25	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	≤0.12	≤0.25						<i>lnuD</i>						
UB46 (Chiba)	2022/Jul	0.12	0.25	≤0.5	≤0.12	≤0.12	0.5	0.25	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25						<i>lnuD</i>						
UB47 (Chiba)	2022/Jul	0.12	0.25	≤0.5	≤0.12	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	≤0.25	<i>blaZ</i>					<i>lnuD</i>						
UB48 (Chiba)	2022/Jul	0.12	0.12	>4	≤0.12	≤0.12	0.25	0.25	<0.5	>1	0.5	≤0.12	0.5	0.5	≤0.25												<i>tet</i> (S)
UB49 (Chiba)	2022/Jul	0.06	0.12	≤0.5	≤0.12	≤0.12	0.25	≤0.12	<0.5	>1	0.5	≤0.12	0.5	0.25	≤0.25					<i>linB</i>							
UB50 (Chiba)	2022/Jul	0.12	0.12	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				
UB51 (Chiba)	2022/Jul	0.06	0.12	1	≤0.12	≤0.12	0.25	≤0.12	<0.5	≤0.12	0.5	≤0.12	0.5	0.25	≤0.25											<i>tet</i> (S)	
UB52 (Chiba)	2022/Jul	0.12	0.12	>4	>2	≤0.12	0.5	0.5	<0.5	>1	0.5	0.25	0.5	0.5	>4			<i>erm</i> (B)					<i>tet</i> (O)				

HK1 (Hokkaido)	2023/Aug	0.25	0.25	>4	>2	≤4	1	0.5	≤0.5	>1	0.5	0.25	0.5	1	>4		erm (B)				tet (O)		
HK2 (Hokkaido)	2023/Aug	0.06	0.25	≤0.5	≤0.12	≤4	1	0.5	≤0.5	≤0.12	0.5	0.25	0.5	1	≤0.25								
HK3 (Hokkaido)	2023/Aug	0.12	0.25	≤0.5	≤0.12	≤4	1	0.5	≤0.5	≤0.12	0.5	0.25	0.5	1	≤0.25								
HK4 (Hokkaido)	2023/Aug	0.12	0.12	≤0.5	≤0.12	≤4	1	0.5	≤0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25								
HK5 (Hokkaido)	2023/Aug	0.12	0.25	≤0.5	≤0.12	≤4	0.5	0.25	≤0.5	≤0.12	1	≤0.12	0.5	0.5	≤0.25								
HK6 (Hokkaido)	2023/Aug	0.12	0.25	>4	>2	≤4	1	0.25	≤0.5	>1	0.5	0.25	0.5	1	>4		erm (B)				tet (O)		
HK7 (Hokkaido)	2023/Aug	0.06	0.12	>4	>2	≤4	0.25	≤0.12	≤0.5	>1	≤0.25	≤0.12	0.5	≤0.12	>4		erm (B)			tet (M)	tet (O)		
HK8 (Hokkaido)	2023/Aug	0.12	0.25	≤0.5	>2	≤4	0.5	0.5	≤0.5	≤0.12	0.5	0.25	0.5	1	4			mef (A)					
HK9 (Hokkaido)	2023/Aug	0.12	0.12	≤0.5	≤0.12	≤4	0.5	0.5	≤0.5	≤0.12	≤0.25	0.25	0.5	0.25	≤0.25					lnuD			
HK10 (Hokkaido)	2023/Aug	0.25	0.25	≤0.5	≤0.12	≤4	1	1	≤0.5	>1	0.5	0.5	0.5	1	≤0.25			linB					
HK11 (Hokkaido)	2023/Aug	0.06	0.12	≤0.5	≤0.12	≤4	0.25	0.25	≤0.5	≤0.12	≤0.25	≤0.12	0.5	0.25	≤0.25								
HK12 (Hokkaido)	2023/Aug	0.12	0.25	≤0.5	≤0.12	≤4	0.5	0.25	≤0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25								
HK13 (Hokkaido)	2023/Aug	0.12	0.25	≤0.5	≤0.12	≤4	0.5	0.25	≤0.5	≤0.12	0.5	0.25	0.5	0.5	≤0.25								
HK14 (Hokkaido)	2023/Aug	0.12	0.12	>4	>2	≤4	1	0.5	≤0.5	>1	0.5	≤0.12	0.5	1	>4		erm (B)				tet (O)		
HK15 (Hokkaido)	2023/Aug	0.12	0.12	1	≤0.12	≤4	0.25	0.25	≤0.5	>1	0.5	0.25	0.5	0.5	≤0.25			linB					
HK16 (Hokkaido)	2023/Aug	0.12	0.25	>4	>2	≤4	0.5	0.5	≤0.5	>1	0.5	0.25	0.5	0.5	>4		erm (B)				tet (O)		
HK17 (Hokkaido)	2023/Sep	0.25	0.25	>4	≤0.12	≤4	0.5	0.5	≤0.5	>1	1	0.25	0.5	1	≤0.25			linB					tet (S)
HK18 (Okinawa)	2023/Sep	0.12	0.25	>4	≤0.12	≤4	0.25	0.25	≤0.5	>1	0.5	0.25	0.5	0.5	≤0.25			linB		lnuD			tet (S)
HK19 (Okinawa)	2023/Sep	0.12	0.25	≤0.5	≤0.12	≤4	0.5	0.25	≤0.5	≤0.12	1	≤0.12	0.5	0.5	≤0.25								
HK20 (Hokkaido)	2023/Sep	0.12	0.25	>4	>2	≤4	0.25	0.25	≤0.5	>1	0.5	0.25	0.5	0.5	>4		erm (B)				tet (O)		

Yellow shading indicates AMR phenotype and genotype. Green shading indicates intermediate susceptibility.

Supplementary Table 2. Oligonucleotide primer set for amplifying antimicrobial resistance gene, their melting temperature (T _m) value, and amplicon size by polymerase chain reaction (PCR)							
Target gene (function or encoding protein)	Primer set	Direction	Sequence (5'→3')	Length (mer)	Expected amplicon size (bp)	T _m value (°C)	Reference
16S rRNA	27F	forward	AGAGTTTGATCMTGGCTCAG	20	1459	52	[4, 17]
(internal control)	1485R	reverse	TACGGTTACCTGTTACGAC	20		49	
<i>bla</i> Z	stau-blaZ-fwd	forward	CAAAGATGATATAGTTGCTTATTCTCC	27	421	54	[16]
(penicillinase)	stau-blaZ-rev	reverse	TGCTTGACCACTTTTATCAGC	21		52	
<i>erm</i> (A)	ermA-F	forward	CCCGAAAAATACGCAAAATTCAT	24	590	53	[5, 11]
(inducible-type methylase)	ermA-R	reverse	CCCTGTTTACCACTTTATAAACG	23		51	
<i>erm</i> (B)	ermB-F	forward	TGGTATCCAAATGCGTAATG	21	745	50	[5, 11]
(constitutive-type methylase)	ermB-R	reverse	CTGTGGTATGGCGGTAAGT	20		53	
<i>mef</i> (A)	mefA-F	forward	CAATATGGGCAGGGCAAG	18	317	51	[5, 11]
(transmembrane domains of an ABC transporter)	mefA-R	reverse	AAGCTGTCCAATGCTACGG	20		54	
<i>linB</i>	linB-F	forward	CCTACCTATTGTTTGTTGGAA	20	945	47	[5]
(lincosamide nucleotidyltransferase)	linB-R	reverse	ATAACGTTACTCTCCTATTC	20		45	
<i>lnuD</i>	lnuD-F	forward	ACGGAGGGATCACATGGTAA	20	475	52	[5]
(lincosamide nucleotidyltransferase)	lnuD-R	reverse	TCTCTCGCATAATAACCTTACGTC	24		55	
<i>tet</i> (M)	tetM-F	forward	GTGGACAAAGGTACAACGAG	20	406	51	[5, 11]
(ribosomal protection protein)	tetM-R	reverse	CGGTAAGTTCGTACACAC	20		51	
<i>tet</i> (O)	tetO-F	forward	AACTTAGGCATTCTGGCTCAC	21	515	54	[5, 11]
(ribosomal protection protein)	tetO-R	reverse	TCCCACTGTCCATATCGTCA	21		53	
<i>tet</i> (K)	tetK-F	forward	GATCAATTGTAGCTTTAGGTGAAGG	25	155	55	[5, 11]
(efflux pump)	tetK-R	reverse	TTTTGTTGATTACCAGGTACCATT	25		52	
<i>tet</i> (L)	tetL-F	forward	TGGTGGAATGATAGCCCAT	20	229	51	[5, 11]
(efflux pump)	tetL-R	reverse	CAGGAATGACAGCACGCTAA	20		54	
<i>tet</i> (S)	tetS-F	forward	TCCGATAGTGATCCCCTTCT	20	445	52	[5, 11]
(ribosomal protection protein)	tetS-R	reverse	GGAAATCTGCTGGCGTACTG	20		54	
T _m value was calculated using nearest neighbor method.							
PCR was done with an initial denaturation at 93°C/3 min, followed by 30 cycles (denaturation at 93°C/1 min, annealing at 62°C/1 min, and extension at 65°C/4 min), and a final extension at 65°C/3 min.							